We would love to hear your thoughts about our site and services, please take our survey here.
Never been a better time to sell part of our assets. We are going to do exceptionally well when we do.
https://www.ft.com/content/ef0cc042-df90-4005-9bd5-65102781704b
Should we sell VXR now?
Change of CEO but no change in direction. Directors and CEO must go or sell up.
Exactly!!! A real deal is getting completed here.
There are 3 world renowned law firms being engaged, which to my way of thinking indicates there are more than one sale probably several, which will all conclude at a date all parties wil have agreed.
Lots of interested parities are trying to get information.
Good days are ahead.
Just updating the current position in the USA. Looking very promising.
Market size analysis and price point sensitivity re-done by top tier US marketing organisation, licensing partners have access to data room and have been updated.
My guess is 12-18 months we will be in a better place.
@RichardDugdale3
To summarise last nights rns-
#Eurasiamining receive offers high enough to allow due diligent access
Rosgeo JV prompted a new offeror who blew offers out the water upon seeing the value of the cornerstone mt
BOD have agreed to the offer and ended FSP in order to accept. #EUA
Amryt said the deal, which would grant it access to Mycapssa, Chiasma’s hormonal disorder drug, would create a global leader in treatments for rare diseases.
It has been approved and recommended by the boards of both companies. Amryt said yesterday that the plan would deliver annual cost synergies of approximately $50 million.
Reason for London fall in SP?
A London-listed biotechnology company specialising in rare diseases has agreed to buy an American rival.News of Amryt Pharma’s $296.7 million all-stock deal for the US-based developer Chiasma propelled shares in its target up by 38.7 per cent to $3.94.